To provide peptides having high affinity for hemagglutinin and peptides having high inhibitory activity against influenza virus infection, as well as pharmaceutical compositions containing the peptides, the polypeptides having any one of SEQ ID NOs: 2 to 7, 9 to 10, and 12 to 18 are obtained by introducing mutation into a peptide having the sequence of ARLSPTMVHPNGAQP (peptide A-1: SEQ ID NO: 1) and screening for peptides having higher affinity for hemagglutinin. Further, the inhibitory activity of the peptide of SEQ ID NO: 3 against influenza virus infection can be enhanced by truncating SEQ ID NO: 3 in its C-terminus region with leaving ARLPR (SEQ ID NO: 44) or ARLP (SEQ ID NO: 52). In addition, an influenza virus-infection inhibitor and an influenza preventive/therapeutic agent can be prepared by formulating these influenza virus receptor-binding peptides.
展开▼
机译：为了提供对血凝素具有高亲和力的肽和对流感病毒感染具有高抑制活性的肽，以及包含所述肽的药物组合物，所述多肽具有SEQ ID NO：2至7、9至10和12至18中任一项。通过将突变引入具有ARLSPTMVHPNGAQP的序列的肽（肽A-1：SEQ ID NO：1）中并筛选对血凝素具有更高亲和力的肽而获得Aβ。此外，可以通过在C末端区域截短SEQ ID NO：3而保留ARLPR（SEQ ID NO：44）或ARLP（SEQ ID NO：3）来增强SEQ ID NO：3的肽对流感病毒感染的抑制活性。 ：52）。另外，可以通过配制这些流感病毒受体结合肽来制备流感病毒感染抑制剂和流感预防/治疗剂。
展开▼
